An In – Depth Look at Tianjin’s Efforts to Accelerate Medical Innovation and Gather Resources:
The People’s Government of Tianjin Municipality has released a set of measures aimed at bolstering the biopharmaceutical industry in the region. These measures seek to accelerate the construction of China’s medical science and technology innovation system Tianjin base and continue to promote the gathering of innovative resources of the Chinese Academy of Medical Sciences in Tianjin.
Key Areas:
The measures focus on the cultivation of distinctive sectors such as synthetic biology, modern Chinese medicine, radiopharmaceuticals, nucleic acid drugs, cell and gene therapy, “AI + medicine”, high – value medical consumables, neuroscience, and regenerative medicine. Drug testing institutions such as Tianjin Institute for Drug Control will be utilized to enhance the testing capabilities of radioactive drugs, nucleic acid drugs, vaccines, cell and gene therapy drugs, imported drugs, and research capabilities for new standards of traditional Chinese medicine.
R & D Support:
Enterprises are encouraged to jointly establish innovation alliances with universities, research institutes, medical institutions, pharmaceutical outsourcing service agencies, etc. These alliances will focus on key technology research and development, new product transformation and application, and platform co – construction. They will also deepen industrial chain and supply chain collaborative innovation cooperation. Innovative entities will be supported to carry out key common technology research and preclinical studies of new drugs. Registration applicants are encouraged to conduct Phase I, II, and III clinical trials at home and abroad. Innovative medical device research and development is supported, and enterprises are encouraged to apply for medical device innovation review and priority approval. Research on post – market evaluation of innovative pharmaceutical and device products is encouraged, as well as real – world efficacy evaluation. Medical institutions are encouraged to optimize their processes and shorten the overall duration of clinical research initiation to within 25 weeks.
Application Support:
An innovative product guidance application catalog will be established and continuously updated. Medical institutions are guided to hold a pharmaceutical meeting within one month after the publication of the application catalog. They are also encouraged to include innovative drugs and devices included in the application catalog into the medical institution’s medication catalog as much as possible. Medical institutions shall not restrict the access of innovative drugs and equipment based on reasons such as the number of drug catalogs or the hospital budget targets. The demonstration application of new technologies such as “AI + medical products” and brain – computer interfaces is supported in medical institutions.
Payment Support:
The inclusion of innovative drugs and devices in the National Reimbursement Drug List (NRDL) is supported. The payment methods for medical insurance will be continuously improved. Innovative drugs in the NRDL used in outpatient diagnosis and treatment will be paid by the medical insurance funds in a timely and full manner. In the DRG/DIP payment mechanism, additional compensation is provided through special case discussions, increased payment points, etc., to support designated medical institutions to standardize the use of innovative drugs with high clinical value. The model of supplying NRDL negotiation drugs through designated medical institutions and designated retail pharmacies will be optimized, prescription circulation supported, and innovative product “dual – channel” sales channels expanded.-Fineline Info & Tech
